Articles published by Akamis Bio

Akamis Bio to Present Initial Data from the Phase 1b FORTRESS Study of NG-350A in Mismatch Repair-Proficient Locally Advanced Rectal Cancer at AACR 2026

Today 16:30 EDT

From Akamis Bio

Via Business Wire

Akamis Bio Receives FDA Fast Track Designation for NG-350A for the Treatment of Mismatch Repair-Proficient Locally Advanced Rectal Cancer

October 14, 2025

From Akamis Bio

Via Business Wire

Akamis Bio Announces the Appointment of Andrew Hirsch to the Company’s Board of Directors

August 12, 2025

From Akamis Bio

Via Business Wire

Akamis Bio Broadens Leadership Team with Key Executive Appointments

May 06, 2025

From Akamis Bio

Via Business Wire

Akamis Bio Announces Enrollment of First Patient in Phase 1b FORTRESS Trial of NG-350A in Patients with Locally Advanced Rectal Cancer

April 03, 2025

From Akamis Bio

Via Business Wire

Akamis Bio Announces $60 Million in Funding Linked to Series A Prime Financing and New Strategic Partnership

December 17, 2024

From Akamis Bio

Via Business Wire

Akamis Bio Announces Publication Detailing Initial Proof of Mechanism for NG-350A, an IV-Dosed Tumor Gene Therapy Delivering a CD40 Agonist Payload

October 23, 2024

From Akamis Bio

Via Business Wire

Akamis Bio Highlights Data Showing Potential of its Adenovirus Vector Technology in Combination with Radiation to Treat Advanced Rectal Cancer

October 03, 2023

From Akamis Bio

Via Business Wire

Akamis Bio Strengthens Leadership Team with Key Executive Appointments

July 06, 2023

From Akamis Bio

Via Business Wire

Akamis Bio, Parker Institute for Cancer Immunotherapy, and Cancer Research Institute Announce Expanded Partnership to Advance Novel Treatments for Pancreatic Cancer

February 16, 2023

From Akamis Bio

Via Business Wire

Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics

January 05, 2023

From Akamis Bio

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.